Bronchopulmonary Dysplasia (BPD) Market Outlook

Thelansis’s “Bronchopulmonary Dysplasia (BPD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Bronchopulmonary Dysplasia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Bronchopulmonary Dysplasia (BPD) Overview

Bronchopulmonary dysplasia (BPD) is the most prevalent chronic respiratory morbidity of prematurity, predominantly afflicting extremely low birth weight (ELBW) infants born prior to 28 weeks of gestation. In the modern post-surfactant era, the pathogenesis of “new BPD” is fundamentally characterized by a critical arrest of both alveolarization and pulmonary microvascular development—resulting in fewer, larger, and highly simplified alveoli—driven by the synergistic, iatrogenic insults of mechanical ventilation (volutrauma and barotrauma) and oxygen toxicity acting upon a profoundly immature and highly inflammatory respiratory system. Clinically defined by a sustained requirement for supplemental oxygen or positive pressure respiratory support at 36 weeks post-menstrual age, the disease initiates a catastrophic cascade that heavily predisposes surviving infants to lifelong sequelae, most notably severe pulmonary hypertension, reactive airway disease, and significant neurodevelopmental impairment. Because definitive pharmacological cures remain elusive, the modern therapeutic paradigm relies heavily on aggressive prevention and lung-protective strategies. The standard of care strictly prioritizes the avoidance of invasive intubation by leveraging early non-invasive continuous positive airway pressure (CPAP), synergistically combined with targeted exogenous surfactant replacement, caffeine citrate therapy, optimized nutritional fortifiers, and the highly judicious administration of postnatal systemic or inhaled corticosteroids to mitigate rampant inflammation and facilitate successful weaning from respiratory support.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025–2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)